BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36410025)

  • 1. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
    Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
    Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of hepatic stem cell factor by Vivo-Morpholino treatment inhibits mast cell migration and decreases biliary damage/senescence and liver fibrosis in Mdr2
    Meadows V; Kennedy L; Hargrove L; Demieville J; Meng F; Virani S; Reinhart E; Kyritsi K; Invernizzi P; Yang Z; Wu N; Liangpunsakul S; Alpini G; Francis H
    Biochim Biophys Acta Mol Basis Dis; 2019 Dec; 1865(12):165557. PubMed ID: 31521820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
    Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
    J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
    Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
    Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
    Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
    Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.
    Kennedy L; Meadows V; Kyritsi K; Pham L; Kundu D; Kulkarni R; Cerritos K; Demieville J; Hargrove L; Glaser S; Zhou T; Jaeger V; Alpini G; Francis H
    Am J Pathol; 2020 May; 190(5):1018-1029. PubMed ID: 32142732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
    Miethke AG; Zhang W; Simmons J; Taylor AE; Shi T; Shanmukhappa SK; Karns R; White S; Jegga AG; Lages CS; Nkinin S; Keller BT; Setchell KD
    Hepatology; 2016 Feb; 63(2):512-23. PubMed ID: 26172874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2
    Kennedy L; Hargrove L; Demieville J; Karstens W; Jones H; DeMorrow S; Meng F; Invernizzi P; Bernuzzi F; Alpini G; Smith S; Akers A; Meadows V; Francis H
    Hepatology; 2018 Sep; 68(3):1042-1056. PubMed ID: 29601088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the
    Fuchs CD; Sroda N; Scharnagl H; Gupta R; Minto W; Stojakovic T; Liles JT; Budas G; Hollenback D; Trauner M
    JHEP Rep; 2023 Nov; 5(11):100874. PubMed ID: 37841639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mast cells selectively target large cholangiocytes during biliary injury via H2HR-mediated cAMP/pERK1/2 signaling.
    Zhou T; Meadows V; Kundu D; Kyritsi K; Owen T; Ceci L; Carpino G; Onori P; Gaudio E; Wu N; Glaser S; Ekser B; Alpini G; Kennedy L; Francis H
    Hepatol Commun; 2022 Oct; 6(10):2715-2731. PubMed ID: 35799467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of p16 Decreases Biliary Damage and Liver Fibrosis in the Mdr2
    Kyritsi K; Francis H; Zhou T; Ceci L; Wu N; Yang Z; Meng F; Chen L; Baiocchi L; Kundu D; Kennedy L; Liangpunsakul S; Wu C; Glaser S; Alpini G
    Gene Expr; 2020 Nov; 20(2):89-103. PubMed ID: 32393417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
    Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
    EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin Receptor-A Inhibition Decreases Ductular Reaction, Liver Fibrosis, and Angiogenesis in a Model of Cholangitis.
    Owen T; Carpino G; Chen L; Kundu D; Wills P; Ekser B; Onori P; Gaudio E; Alpini G; Francis H; Kennedy L
    Cell Mol Gastroenterol Hepatol; 2023; 16(4):513-540. PubMed ID: 37336290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary damage and liver fibrosis are ameliorated in a novel mouse model lacking l-histidine decarboxylase/histamine signaling.
    Kennedy L; Meadows V; Demieville J; Hargrove L; Virani S; Glaser S; Zhou T; Rinehart E; Jaeger V; Kyritsi K; Pham L; Alpini G; Francis H
    Lab Invest; 2020 Jun; 100(6):837-848. PubMed ID: 32054995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged darkness reduces liver fibrosis in a mouse model of primary sclerosing cholangitis by miR-200b down-regulation.
    Wu N; Meng F; Zhou T; Han Y; Kennedy L; Venter J; Francis H; DeMorrow S; Onori P; Invernizzi P; Bernuzzi F; Mancinelli R; Gaudio E; Franchitto A; Glaser S; Alpini G
    FASEB J; 2017 Oct; 31(10):4305-4324. PubMed ID: 28634212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
    Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
    Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.
    Reich M; Spomer L; Klindt C; Fuchs K; Stindt J; Deutschmann K; Höhne J; Liaskou E; Hov JR; Karlsen TH; Beuers U; Verheij J; Ferreira-Gonzalez S; Hirschfield G; Forbes SJ; Schramm C; Esposito I; Nierhoff D; Fickert P; Fuchs CD; Trauner M; García-Beccaria M; Gabernet G; Nahnsen S; Mallm JP; Vogel M; Schoonjans K; Lautwein T; Köhrer K; Häussinger D; Luedde T; Heikenwalder M; Keitel V
    J Hepatol; 2021 Sep; 75(3):634-646. PubMed ID: 33872692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
    Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
    Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.